Tag Archive for: financing

Hemab Therapeutics A/S has completed an oversubscribed US$157m Series C financing round led by Sofinnova Partners to accelarate and expand its pipeline in bleeding disorders and thrombosis treatments.

French ADC start-up Adcytherix SAS has added €105m Series A funding to a €30m seed financing round closed last year. With the money, the company will start a Phase I study with its lead ADCX-020 in Q1 2026 and develop novel payloads to break ADC therapy resistance.

Lisbon’s immuno-oncology company Mondego Bio Lda has left stealth mode through a Series A financing led by Biovance Capital, supported by OrbiMed and Torrey Pines.

British antibody specialist Alchemab Therapeutics Ltd has secured a US$32m Series A extension after it completing preclinical development of ATLX-1282 and starting a Phase I clinical trial.

British mitochondrial dysfunction specialist NRG Therapeutics Ltd. (“NRG”) has closed an oversubscribed £50m Series B financing. Funds will be used to to achieve clinical proof of concept for NRG5051 in amyotrophic lateral sclerosis (ALS)/motor neurone disease (MND) and to generate Phase Ib data in Parkinson’s disease.

Swedish immunoncology specialist Anocca AB has raised SEK440m (€38.36m) ahead of enrolling pancreatic cancer patients in a Phase I umbrella trial evaluating the safety of its T-cell receptor-engineered T cell (TCR-T) programmes ANOC-001, ANOC-002 and ANOC-003.

German CPTx GmbH, its CDMO Gxstrands, and the US start-up NanoCell Therapeutics have been awarded a Eurostars grant for their QUIET-CAR project, funded through the EU’s Horizon Europe programme and the Eureka Network. The focus of the project will be on the development of scalable in-vivo CAR-T therapies against cancer and autoimmune diseases.

British targeted gene silencing specialist Laverock Therapeutics Ltd has expanded its seed funding to £20m by a new financing round led by xx and xx. The company said it will use the funds to…l

SpliceBio SL has baged US$135m in a Series B financing co-led by EQT Life Sciences and Sanofi Ventures, with participation from Roche Venture Fund, as well as all existing investors The Barcelona-based company will use the proceeds to advance SB-007 in Stargardt disease and expand its pipeline of meds that regulate splicing.

Obstructive sleep apnea (OSA) specialist Mosanna Therapeutics AG has secured US$80m in a Series A financing to fund clinical testing through Phase II of its nasal OSA spray MOS118.